SEHK:9926Biotechs
Akeso Data And INOVIO Deal Deepen Immunotherapy And Valuation Story
Akeso (SEHK:9926) reported long term survival data for cadonilimab in advanced cervical cancer, with benefits extending to patients who are PD L1 negative or resistant to prior therapies.
The company also entered a collaboration with INOVIO to study a combination immunotherapy approach for glioblastoma.
Akeso focuses on immuno oncology drugs, and cadonilimab is one of its key assets in gynecologic cancers. The fresh data around long term outcomes in advanced cervical cancer reinforces the...